期刊
BLOOD REVIEWS
卷 56, 期 -, 页码 -出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2022.100968
关键词
Adverse events; Chronic myeloid leukemia; Long-term; Safety; Tyrosine kinase inhibitors
类别
资金
- Pfizer Inc.
The development of BCR::ABL1-targeting tyrosine kinase inhibitors has improved the prognosis of patients with chronic myeloid leukemia. Differences in safety profiles between TKIs allow for personalized treatment plans based on various factors. This review summarizes the safety profiles of currently approved TKIs and their impact on treatment selection, as well as strategies to manage adverse events and comorbidities.
The development of BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myeloid leukemia (CML). Although there are some common class-wide side effects, differences in safety profiles between TKIs allow physicians and patients to personalize treatment plans. Treatment selection depends on several factors, such as age, disease risk, comorbidities, and concomitant medications. In second-and later-line settings, response to previous TKIs and mutation analyses should also be used to guide TKI selection. Several strategies can be used to manage adverse events (AEs) that emerge during treatment, e.g., dose re-ductions/interruptions, monitoring, treatment of AEs, lifestyle modifications, prophylactic therapy, and other supportive care strategies. This review summarizes the safety profiles of the currently approved TKIs and how they impact treatment selection in the first-and later-line settings of CML, particularly regarding patient comorbidities and concomitant medications. Additionally, strategies to manage AEs of special interest with TKIs are reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据